





Dihydroartemisinin + piperazine

Essential medicine status 

Section: [6. Anti-infective medicines](#) > [6.5. Antiprotozoal medicines](#) > [6.5.3. Antimalarial medicines](#) > [6.5.3.1. Antimalarial medicines](#) > Medicines for curative treatment

| | | |
|---------------------------------|---|---------------------------|
| | EMLc | ATC codes: P01BF05 |
| Indication | Malaria due to Plasmodium falciparum | ICD11 code: 1F40 |
| Medicine type | Chemical agent | |
| List type | Core (EML) (EMLc) | |
| Formulations | Oral > Solid > dispersible tablet: 20 mg + 160 mg (phosphate) (EMLc) ; 40 mg + 320 mg (phosphate) (EMLc) Oral > Solid > tablet: 40 mg + 320 mg (phosphate) ; 20 mg + 160 mg (phosphate) ; 60 mg + 480 (phosphate) ; 80 mg + 640 mg (phosphate) | |
| EML status history | First added in 2017 (TRS 1006) Changed in 2025 (TRS 1064) | |
| Sex | All | |
| Age | Also recommended for children | |
| Therapeutic alternatives | The recommendation is for this specific medicine | |
| Patent information | Patents have expired in most jurisdictions Read more about patents .  | |
| Wikipedia | Dihydroartemisinin + piperazine  | |
| DrugBank | Artemimol  , Piperazine  | |

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of two new strengths of tablets (60mg + 480 mg and 80 mg + 840 mg) on the EML and EMLc; - the addition of two new strengths of dispersible tablets (20 mg + 160 mg and 40 mg + 320 mg) on the EMLc; - removal of the weight restriction, in recognition that use should be in line with recommendations with WHO guidelines; - to update the listing to include reference to the phosphate salt of piperazine in the formulation description instead of the medicine name.

